Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term phase 3 extension study of remibrutinib in adults and adolescents with moderate to severe hidradenitis suppurativa
CTR20262784Phase 3Active
- Sponsor
- 不适用/ 诺华（中国）生物医学研究有限公司
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of remibrutinib in hidradenitis suppurativa (HS), sponsored by 不适用/ 诺华（中国）生物医学研究有限公司. Started Jul 2026; status: active.
02
Drugs
remibrutinib
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on CTR20262784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262784.